Medical News
Global Oncology Partnership Panel Focuses on Patient Engagement
Patient advocates gathered at the first Global Oncology Partnership Panel (GOPP) meeting hosted by Boehringer Ingelheim in Germany. Workshops and d...
Ensuring Access to Critical Medicines: What Digestive Cancer Patients Need from the Critical Medicines Act
The European Commission’s proposal for a Critical Medicines Act marks a significant step toward securing the supply, availability, and accessib...
Can a Targeted Cancer Drug Help Prevent Recurrence in Gastro-Oesophageal Cancer?
DECIPHER Trial for patients with gastro-oesophageal adenocarcinoma, tests whether a targeted cancer drug can help patients with a hard-to-treat can...
Educational Programme on Metastatic Pancreatic Cancer Now Available
Metastatic pancreatic ductal adenocarcinoma (mPDAC) is an aggressive and often late-diagnosed cancer with poor prognoses. Early detection remains c...
Advancing Liver Cancer Care: Highlights from the BCLC 2024 Meeting
On November 25th and 26th, DiCE virtually attended the Barcelone Clinic Liver Cancer (BCLC) annual conference, which was titled “Forging a Multid...
Tevimbra (tislelizumab) Receives New European Recommendations for Oesophageal and Gastric Cancer
Tevimbra (tislelizumab) receives CHMP recommendations for treating PD-L1-positive oesophageal squamous cell carcinoma and gastric/gastroesophageal ...
New Era in Gastric Cancer Treatment: Zolbetuximab Gains EU Approval
On September 20th, 2024, the European Commission approved zolbetuximab with chemotherapy for advanced Gastric and GastroEsophageal Junction cancers...
The POLAR Promise: Groundbreaking Survival Gains for Targeted Pancreatic Cancer Patients in Phase II Trial
Phase II trial of Pembrolizumab Immunotherapy and Olaparib (POLAR) trial new data presented at the European Society for Medical Oncology (ESMO) 202...
DiCE at ESMO 2024
Earlier this month, part of the DiCE Medical and Scientific Team attended the ESMO (European Society for Medical Oncology) Congress 2024 in Barcelo...
EMA Approves New First-line Treatment Option for Metastatic Pancreatic Cancer
Irinotecan hydrochloride trihydrate (Onivyde pegylated liposomal) was approved in March 2024 by the European Medicines Agency (EMA). Indications: N...